OTCMKTS:IDRSF Idorsia (IDRSF) Stock Price, News & Analysis $2.75 +0.35 (+14.58%) As of 03:55 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Idorsia Stock (OTCMKTS:IDRSF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Idorsia alerts:Sign Up Key Stats Today's Range$2.75▼$2.7550-Day Range$1.00▼$2.4052-Week Range$0.70▼$2.75Volume2,193 shsAverage Volume1,044 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia. The company has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and commercialize PIVLAZ. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland. Read More Receive IDRSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter. Email Address IDRSF Stock News HeadlinesA factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humansJune 30, 2025 | globenewswire.comIdorsia Pharmaceuticals Ltd: Bondholders approve amended terms of the 2025 and 2028 convertible bondsJune 25, 2025 | finanznachrichten.deWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. July 7 at 2:00 AM | Altimetry (Ad)Idorsia launches repurchase offer for its 2025 and 2028 convertible bondsJune 25, 2025 | globenewswire.comIdorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreementJune 24, 2025 | uk.finance.yahoo.comIdorsia Pharmaceuticals Ltd: Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of IdorsiaJune 10, 2025 | finanznachrichten.deIdorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of IdorsiaJune 10, 2025 | globenewswire.comIdorsia Pharmaceuticals Ltd: Idorsia publishes invitations to bondholder meetingsJune 6, 2025 | finanznachrichten.deSee More Headlines IDRSF Stock Analysis - Frequently Asked Questions How have IDRSF shares performed this year? Idorsia's stock was trading at $0.85 on January 1st, 2025. Since then, IDRSF shares have increased by 223.5% and is now trading at $2.75. How do I buy shares of Idorsia? Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/07/2025Next Earnings (Estimated)7/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:IDRSF CIKN/A Webwww.idorsia.com Phone(158) 844-0000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (OTCMKTS:IDRSF) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idorsia Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Idorsia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.